Idraparinux sodium for the treatment and secondary prevention of recurrent venous thromboembolism (VTE) - horizon scanning review
NHSC
Record ID 32004000887
English
Authors' objectives:
This study aims to summarise the currently available evidence on idraparinux sodium for the treatment and secondary prevention of recurrent venous thromboembolism (VTE).
Authors' recommendations:
Idraparinux sodium (SanOrg-34006) is a long-acting antithrombotic agent in phase III clinical trials for the treatment and secondary prevention of recurrent VTE in patients with acute symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE). Idraparinux is administered as a once weekly subcutaneous injection. A 12-week phase II trial found an equivalent anticoagulation effect to warfarin with a significantly reduced risk of bleeding in the 2.5mg group (the dose being used in the ongoing phase III trials). Idraparinux is also in clinical trials for the prevention of VTE associated with atrial fibrillation (AF).
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2004
URL for published report:
http://www.psy-flow.com/sites/psy-flow/files/docs/flow.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Anticoagulants
- Thromboembolism
- Venous Thrombosis
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.